Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03024216 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
A Phase 1 study, sponsored by University of Hawaii.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT03024216 is a Phase 1 study that has completed, run by University of Hawaii. The registered enrollment target is 37 participants.
The verdict
NCT03024216, a Phase 1 study, has completed, sponsored by University of Hawaii.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the safety and tolerability of sequential atezolizumab followed by sipuleucel-T (Arm 1) vs. sipuleucel-T followed by atezolizumab (Arm 2) in patients who have asymptomatic or minimally symptomatic metastatic CRPC, not previously treated with docetaxel or cabazitaxel.
Interventions
- DRUG Sipuleucel-T
- DRUG Atezolizumab1200 mg IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03024216
The ClinicalTrials.gov registry entry for NCT03024216 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Hawaii, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sipuleucel-T is the first listed.
NCT03024216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03024216 about?
NCT03024216 is a clinical study titled "Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer". The purpose of the study is to compare the safety and tolerability of sequential atezolizumab followed by sipuleucel-T (Arm 1) vs. sipuleucel-T followed by atezolizumab (Arm 2) in patients who have asymptomatic or minimally symptomatic metastatic CRPC, not previously treated with docetaxel or cabazi...
What is the current status of trial NCT03024216?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2017-02-06. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03024216?
The interventions under investigation include: Sipuleucel-T (DRUG), Atezolizumab1200 mg IV (DRUG).
Who is sponsoring clinical trial NCT03024216?
This trial is sponsored by University of Hawaii, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.